Logo image of ADN

ADVENT TECHNOLOGIES HOLDINGS (ADN) Stock Fundamental Analysis

NASDAQ:ADN - Nasdaq - US00788A2042 - Common Stock - Currency: USD

1.97  -0.02 (-1.01%)

After market: 1.97 0 (0%)

Fundamental Rating

1

Taking everything into account, ADN scores 1 out of 10 in our fundamental rating. ADN was compared to 93 industry peers in the Electrical Equipment industry. Both the profitability and financial health of ADN have multiple concerns. While showing a medium growth rate, ADN is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year ADN has reported negative net income.
ADN had a negative operating cash flow in the past year.
ADN had negative earnings in each of the past 5 years.
ADN had a negative operating cash flow in each of the past 5 years.
ADN Yearly Net Income VS EBIT VS OCF VS FCFADN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M

1.2 Ratios

The Return On Assets of ADN (-571.42%) is worse than 96.77% of its industry peers.
Industry RankSector Rank
ROA -571.42%
ROE N/A
ROIC N/A
ROA(3y)-266.83%
ROA(5y)-195.57%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ADN Yearly ROA, ROE, ROICADN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 0 -200 -400

1.3 Margins

ADN has a better Gross Margin (54.58%) than 97.85% of its industry peers.
ADN's Gross Margin has improved in the last couple of years.
The Profit Margin and Operating Margin are not available for ADN so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 54.58%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y32.39%
GM growth 5Y8.72%
ADN Yearly Profit, Operating, Gross MarginsADN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 0 -1K -2K -3K -4K

More info and screens

0

2. Health

2.1 Basic Checks

ADN does not have a ROIC to compare to the WACC, probably because it is not profitable.
ADN has more shares outstanding than it did 1 year ago.
ADN has more shares outstanding than it did 5 years ago.
The debt/assets ratio for ADN is higher compared to a year ago.
ADN Yearly Shares OutstandingADN Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 500K 1M 1.5M 2M 2.5M
ADN Yearly Total Debt VS Total AssetsADN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

2.2 Solvency

ADN has an Altman-Z score of -56.36. This is a bad value and indicates that ADN is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of ADN (-56.36) is worse than 95.70% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -56.36
ROIC/WACCN/A
WACC10.22%
ADN Yearly LT Debt VS Equity VS FCFADN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 50M 100M

2.3 Liquidity

ADN has a Current Ratio of 0.06. This is a bad value and indicates that ADN is not financially healthy enough and could expect problems in meeting its short term obligations.
ADN has a worse Current ratio (0.06) than 93.55% of its industry peers.
ADN has a Quick Ratio of 0.06. This is a bad value and indicates that ADN is not financially healthy enough and could expect problems in meeting its short term obligations.
ADN has a worse Quick ratio (0.06) than 93.55% of its industry peers.
Industry RankSector Rank
Current Ratio 0.06
Quick Ratio 0.06
ADN Yearly Current Assets VS Current LiabilitesADN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

More info and screens

4

3. Growth

3.1 Past

ADN shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 57.98%, which is quite impressive.
Looking at the last year, ADN shows a very strong growth in Revenue. The Revenue has grown by 113.28%.
The Revenue has been growing by 39.50% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)57.98%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%65.69%
Revenue 1Y (TTM)113.28%
Revenue growth 3Y-22.61%
Revenue growth 5Y39.5%
Sales Q2Q%-96.23%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y600%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year91.56%
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ADN Yearly Revenue VS EstimatesADN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M 200M
ADN Yearly EPS VS EstimatesADN Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 0 -5 -10 -15 -20

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

ADN reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
With a Price/Forward Earnings ratio of 19.50, ADN is valued on the expensive side.
Based on the Price/Forward Earnings ratio, ADN is valued a bit cheaper than the industry average as 78.49% of the companies are valued more expensively.
ADN is valuated rather cheaply when we compare the Price/Forward Earnings ratio to 37.78, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE N/A
Fwd PE 19.5
ADN Price Earnings VS Forward Price EarningsADN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ADN Per share dataADN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -5 -10 -15

4.3 Compensation for Growth

ADN's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ADN!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ADVENT TECHNOLOGIES HOLDINGS

NASDAQ:ADN (7/28/2025, 8:06:23 PM)

After market: 1.97 0 (0%)

1.97

-0.02 (-1.01%)

Chartmill FA Rating
GICS SectorIndustrials
GICS IndustryGroupCapital Goods
GICS IndustryElectrical Equipment
Earnings (Last)06-30 2025-06-30/amc
Earnings (Next)10-20 2025-10-20
Inst Owners7.03%
Inst Owner Change0%
Ins Owners11.63%
Ins Owner Change0%
Market Cap5.26M
Analysts45
Price TargetN/A
Short Float %0.98%
Short Ratio0.49
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 19.5
P/S 1.61
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-15.65
EYN/A
EPS(NY)0.1
Fwd EY5.13%
FCF(TTM)-1.33
FCFYN/A
OCF(TTM)-1.29
OCFYN/A
SpS1.23
BVpS-9.24
TBVpS-9.28
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -571.42%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 54.58%
FCFM N/A
ROA(3y)-266.83%
ROA(5y)-195.57%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y32.39%
GM growth 5Y8.72%
F-Score4
Asset Turnover0.46
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 7.76%
Cap/Sales 2.53%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.06
Quick Ratio 0.06
Altman-Z -56.36
F-Score4
WACC10.22%
ROIC/WACCN/A
Cap/Depr(3y)123.72%
Cap/Depr(5y)228.29%
Cap/Sales(3y)123.53%
Cap/Sales(5y)88.03%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)57.98%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%65.69%
EPS Next Y600%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)113.28%
Revenue growth 3Y-22.61%
Revenue growth 5Y39.5%
Sales Q2Q%-96.23%
Revenue Next Year91.56%
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y55.14%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year760%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y90.13%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y85.76%
OCF growth 3YN/A
OCF growth 5YN/A